Loading...
•
Dec 31, 2019
CorMedix Q4 2019 Earnings Report
Reported a net loss due to reversal of clinical trial expenses and provided a business update.
Key Takeaways
CorMedix reported a net loss of $5.3 million for Q4 2019, compared to a net income of $2.2 million in Q4 2018. The company is in the process of submitting a New Drug Application (NDA) for Neutrolin.
Received FDA agreement to submit NDA on a rolling basis and commenced the submission process.
Planning to continue filing schedule and be on track for a decision in the second half of 2020.
Net loss attributable to common shareholders was $5.3 million, or $0.21 per share.
Operating expenses were $5.4 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...